Table 4.
Distribution of relevant demographic and clinical characteristics by subtypes in the FH cohort.
| Subtype 1 | Subtype 2 | Subtype 3 | Subtype 4 | p-value | ||
|---|---|---|---|---|---|---|
| Age | Median (25%, 75%) | 60 (53, 64) | 57 (51, 61) | 61 (56, 64) | 60 (56, 65) | 6.28×10−6 |
| Race | ||||||
| Caucasian | 106 (86%) | 203 (97%) | 93 (96%) | 28 (100%) | 1.36×10−3 | |
| African American | 17 (14%) | 7 (3%) | 4 (4%) | 0 (0%) | ||
| Gleason Score | ||||||
| <= 6 | 67 (54%) | 110 (52%) | 34 (35%) | 6 (21%) | ||
| 7 (3+4) | 42 (34%) | 75 (36%) | 35 (36%) | 14 (51%) | 1.08×10−3 | |
| 7 (4+3) | 8 (7%) | 13 (6%) | 16 (16%) | 4 (14%) | ||
| 8–10 | 6 (5%) | 12 (6%) | 12 (12%) | 4 (14%) | ||
| PSA (ng/mL) at diagnosis | ||||||
| <4 | 18 (15%) | 36 (17%) | 14 (14%) | 2 (7%) | ||
| 4–10 | 79 (64%) | 132 (63%) | 47 (48%) | 16 (57%) | ||
| 10–20 | 14 (11%) | 20 (10%) | 20 (21%) | 6 (21%) | 0.031 | |
| ≥20 | 3 (2%) | 11 (5%) | 9 (9%) | 3 (11%) | ||
| Missing | 9 (7%) | 11 (5%) | 7 (7%) | 1 (4%) | ||
| Stage | ||||||
| Local/T2 | 94 (76%) | 141 (67%) | 63 (65%) | 14 (50%) | 0.034 | |
| Regional/T3 | 29 (24%) | 69 (33%) | 34 (35%) | 14 (50%) | ||
| TMPRSS2-ERG gene fusion | ||||||
| No fusion | 95 (77%) | 27 (13%) | 53 (55%) | 23 (82%) | ||
| Fusion | 19 (15%) | 172 (82%) | 41 (42%) | 3 (11%) | 1.8×10−35 | |
| Missing | 9 (7%) | 11 (5%) | 3 (3%) | 2 (7%) | ||